A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology.

Natera, Inc. NTRA recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Roche RHHBY announced that the FDA has approved a label expansion for Tecentriq (atezolizumab) and Tecentriq Hybreza ...

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

From new immunotherapy approaches to insights into environmental risk, research presented at the American Urological Association (AUA) Annual Meeting in Washington, DC, highlights meaningful progress ...

Bladder cancer is one of the most common, and most overlooked, cancers in the United States, impacting hundreds of thousands of families each year. This is a public health issue that touches families, ...

Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...

But when Jimi began experiencing bladder cancer symptoms, including blood in his urine, he felt a different kind of rush. It ...

Getting your Trinity Audio player ready... By DEVI SHASTRI Colorado football coach Deion Sanders was diagnosed with an aggressive form of bladder cancer earlier this year, had surgery to remove the ...